p53 antagonists are available [227]; however, systemically reducing the expression of the p16Ink4a or p53-p21Cip1/Waf1 pathways would likely increase risk of cancer [228,229,230,231], because inhibiting the ability to form senescent cells appears to allow DNA-damaged cells to continue to proliferate. Here, CDKN1A is linked to cancer.